News & Updates

Show Multimedia Only

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

20 Jan 2023 by

Use of FRSW 107, a novel homodimer recombinant factor VIII (rFVIII) Fc fusion protein, for prophylaxis and treatment of bleeding episodes is both safe and effective among previously treated adolescent and adult patients with haemophilia A (HA), reports a China study presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

20 Jan 2023

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

20 Jan 2023

Robotic-assisted bronchoscopy (RAB) appears to be as reliable as computed tomography-guided transthoracic biopsy (CTTB) in sampling pulmonary nodules with similar or reduced complications, a study has shown.

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

20 Jan 2023

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023 by

Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

20 Jan 2023

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

20 Jan 2023

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023 by

Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023

Death after out-of-hospital cardiac arrest highest within first 3 years

19 Jan 2023 by

The mortality rate following an incidence of out-of-hospital cardiac arrest (OHCA) is highest in the first 3 years post-event, gradually reducing over time, according to a study from Singapore.

Death after out-of-hospital cardiac arrest highest within first 3 years

19 Jan 2023

Total diet replacement shows promise for difficult-to-treat asthma

19 Jan 2023

A low-calorie total diet replacement program (Counterweight-Plus) is safe and improves asthma control and quality of life in patients with difficult-to-treat asthma and obesity, according to 16-week data from a recent study.

Total diet replacement shows promise for difficult-to-treat asthma

19 Jan 2023

Lung cancer ups mortality risk in IPF patients

19 Jan 2023

A diagnosis of lung cancer can significantly worsen survival in patients with idiopathic pulmonary fibrosis (IPF), reports a study.

Lung cancer ups mortality risk in IPF patients

19 Jan 2023

Mitapivat maintains long-term Hb response in PK deficiency patients

19 Jan 2023 by

Treatment with mitapivat results in long-term and durable improvements in haemoglobin (Hb) and a decrease in transfusion burden over several years in patients with pyruvate kinase (PK) deficiency, according to the results of a study, which was presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

Mitapivat maintains long-term Hb response in PK deficiency patients

19 Jan 2023

Idiopathic/local factor NC-SVT ups risk of recurrent thrombosis

19 Jan 2023

The risk of overall recurrent thrombosis (RT) is greater among individuals with idiopathic/local factor-related noncirrhotic splanchnic vein thrombosis (NC-SVT), reveals a study. Moreover, splanchnic RT can appear without symptoms and requires screening to be detected.

Idiopathic/local factor NC-SVT ups risk of recurrent thrombosis

19 Jan 2023

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

FRSW 107 proven safe, effective in previously treated patients with haemophilia A

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

Robotic-assisted bronchoscopy on par with biopsy for nodules diagnosis

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

TNFα antagonists, non-TNF biologics both safe for treating IBD in cancer patients

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

Death after out-of-hospital cardiac arrest highest within first 3 years

Death after out-of-hospital cardiac arrest highest within first 3 years

Total diet replacement shows promise for difficult-to-treat asthma

Total diet replacement shows promise for difficult-to-treat asthma

Lung cancer ups mortality risk in IPF patients

Lung cancer ups mortality risk in IPF patients

Mitapivat maintains long-term Hb response in PK deficiency patients

Mitapivat maintains long-term Hb response in PK deficiency patients

Idiopathic/local factor NC-SVT ups risk of recurrent thrombosis

Idiopathic/local factor NC-SVT ups risk of recurrent thrombosis